SIENA, SALVATORE

SIENA, SALVATORE  

Dipartimento di Oncologia ed Emato-Oncologia  

Mostra records
Risultati 1 - 20 di 383 (tempo di esecuzione: 0.008 secondi).
Titolo Data di pubblicazione Autori Tipo File Abstract
8C.04: possible role of arterial function in cancer treatment targeting vascular endothelial growth factor receptor oncologic response 1-giu-2015 S. Siena + Article (author) -
[Clinical use of hematopoietic growth factors] 1-giu-1991 A. M. GianniS. SienaC. Tarella + Article (author) -
[Long-term hematopoietic reconstitution after myeloablative antitumor therapy and circulating hematopoietic stem cell transplantation] 1-gen-1996 S. SienaA. M. Gianni + Article (author) -
A case of metastatic axillary lymph nodes involvement from unknown primary cancer: Clinical usefulness of [Tc-99m]-sestamibi 1-gen-1998 Siena, S + Article (author) -
A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily Filgrastim in patients with stage II-IV breast cancer 1-gen-2003 Siena, Salvatore + Article (author) -
A comprehensive PDX gastric cancer collection captures cancer cell intrinsic transcriptional MSI traits 1-nov-2019 Pietrantonio, FilippoSiena, SalvatoreSartore-Bianchi, Andrea + Article (author) -
A cup of coffee for allergic rhinitis 1-gen-1982 Siena S. + Article (author) -
A Genomic Analysis Workflow for Colorectal Cancer Precision Oncology 7-mar-2019 Siena, Salvatore + Article (author) -
A molecularly annotated platform of patient- derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer 1-gen-2011 G. MigliardiE. ValtortaA. Sartore BianchiS. Siena + Article (author) -
A Multicenter Phase II Study of AMG 337 in Patients with MET-Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma and Other MET-Amplified Solid Tumors 1-gen-2019 Siena, Salvatore + Article (author) -
A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment 1-gen-2020 Siena, Salvatore + Article (author) -
A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer 1-gen-2008 S. Siena + Article (author) -
A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy 1-gen-2003 Siena S. + Article (author) -
A standardized flow cytometry protocol for mobilized peripheral CD34+ cells estimation and collection for autotransplantation in cancer patients 1-gen-1994 S. SienaA. M. Gianni + Article (author) -
A subset of colorectal cancers with cross-sensitivity to olaparib and oxaliplatin 1-gen-2020 Pagani, MassimilianoMauri, GianlucaSartore-Bianchi, AndreaAbrignani, SergioSiena, Salvatore + Article (author) -
A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer : the 'BRAF BeCool' study 1-set-2019 Sartore-Bianchi, AndreaPietrantonio, FilippoSiena, Salvatore + Article (author) -
Absence of c-kit and members of the epidermal growth factor receptor family in refractory germ cell cancer (multiple letters) 1-gen-2003 Siena S. + Article (author) -
Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer 1-gen-2016 E. ValtortaF. PietrantonioS. SienaA. Sartore-Bianchi + Article (author) -
Acquired resistance to EGFR-targeted therapies incolorectal cancer 1-set-2014 A. Sartore BianchiS. Siena + Article (author) -
Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer 1-gen-2016 A. Sartore BianchiS. Siena + Article (author) -